A phase 2 clinical trial of LB P8 for the treatment of Non-alcoholic-steatohepatitis (NASH)
Latest Information Update: 12 Jan 2022
At a glance
- Drugs LB-P8 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 06 Jan 2022 According to a LISCure Biosciences media release, this trial is planned to initiate in 2H 2022.
- 02 Aug 2021 New trial record
- 26 Jul 2021 According to a LISCure Biosciences media release, company plans to minimize trial and error in preparation for this trial in 2022 by jointly cooperating with Mayo Clinic.